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Abstract
Background and aims: Anemia and increased 
LQÀDPPDWLRQDUHWKHPDLQFDXVHVRIPRUWDOLW\LQ
chronic kidney disease (CKD) patients. This study 
was designed to explore the probable relationship 
of hemoglobin (Hb) with serum haptoglobin (HP), 
LWV JHQRW\SHV DQG LQÀDPPDWLRQ VWDWXHV LQ &.'
stage 4 patients with anemia.
Methods: The subjects of the study was 40 ane-
PLF&.'SDWLHQWVRQVWDJH>*)5 PO
min/1.73 m2]. Serum biochemical factors as well 
as ferritin, HP and IL-6 levels were measured by 
standard methods. Haptoglobin genotypes were 
determent by PCR method and the accuracy of ge-
QRW\SLQJZDVFRQ¿UPHGE\VHTXHQFLQJDPSOL¿HG
fragments and RFLP analysis. 
Results: Results showed that although HP2-2 
ZDV WKHPRVWFRPPRQJHQRW\SHQRVL-
JQL¿FDQWFRUUHODWLRQVEHWZHHQ+3JHQRW\SHVZLWK
+EDQG+3OHYHOVZHUHIRXQGS S 
UHVSHFWLYHO\ 6LJQL¿FDQW QHJDWLYH FRUUHODWLRQ
EHWZHHQ+EOHYHOZLWK,/DQGKV&53OHYHOVS
DQGSUHVSHFWLYHO\DQGDVLJQL¿FDQW
positive correlation between Hb and ferritin levels 
ZDVIRXQGS
Conclusion: The results suggest that HP ge-
QRW\SH DQG VHUXP+3 OHYHOV KDYHQR VLJQL¿FDQW
effect on hemoglobin level in CKD stage 4 pa-
tients. However, Hb level is associated with in-
ÀDPPDWLRQDQGDOEXPLQVWDWXV
Keywords: Haptoglobin genotype, CKD, he-
PRJORELQLQÀDPPDWLRQ
Introduction
The incidence and prevalence of kidney di-
sease worldwide has risen markedly in the past 
decade [1]. It has been shown that, the incidence 
of chronic kidney disease (CKD) in stages 3 to 5, 
LQ,UDQLVDERXW>@&KURQLFNLGQH\GLVHD-
VH LV WKHPRVWFRPPRQO\GH¿QHGE\DUHGXFWLRQ
in kidney function [3]. The anemia is a common 
complication in patients with CKD and correlates 
VLJQL¿FDQWO\ZLWK WKHPRUELGLW\DQGPRUWDOLW\ LQ
these patients [4].
The main causes of anemia in CKD are redu-
ced production of erythropoietin in the kidneys 
DQGHU\WKURSRLHWLQUHVLVWDQFH>@,QÀDPPDWLRQ
also has an important role in CKD complicati-
RQV>@,QÀDPPDWRU\IDFWRUVVXFKDV,/LQKLELW
erythropoietin production, impair the growth of 
erythroblasts, decreases RBC survival and pro-
mote death of immature erythroblasts [5, 7]. Stu-
dies shown that patients who had higher plasma 
OHYHOVRI LQÀDPPDWRU\PDUNHUVVKRZVORZHUKH-
moglobin levels than those with lower level of in-
ÀDPPDWLRQ>@2QWKHRWKHUKDQG,QÀDPPDWLRQ
is an important factor associated with erythropoie-
tin resistance and the occurrence of anemia in pa-
WLHQWVZLWK&.'>@,QÀDPPDWLRQDOVROLPLWVWKH
availability of iron for erythropoiesis and expands 
the erythropoietin resistance [10]. One of the ma-
MRULQGXFLEOHF\WRNLQHLQÀDPPDWRU\SURWHLQVWKDW
participate in hemoglobin and iron metabolism 
called haptoglobin (HP) [11]. Haptoglobin is the 
major hemoglobin-binding protein in the plasma 
of most vertebrates and all mammals [12]. Hap-
toglobin is synthesized primarily via hepatocytes 
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and expressed by a genetic polymorphism as three 
major genotypes HP1-1, HP2-1, HP2-2 [13]. Both 
HP 1 and HP 2 alleles have been found in all popu-
lation, although their frequencies vary considera-
bly among them [14]. The primary physiological 
function of HP has been described in terms of its 
interaction with free Hb and prevents hemoglobin 
deposition in the glomeruli and proximal tubule 
cells of the kidney and prevents body iron loss 
[15]. In CKD patients, uremic toxins can shor-
ten the erythrocyte life span leading to hemolysis 
and contribute to renal anemia [5, 16]. It has been 
shown that the different HP genotypes have diffe-
rent effects on the rate of uptake and removal of 
hemoglobin released from erythrocytes [17]. The 
other possible function of HP is the participation in 
iron metabolism as HP affects the regulation of the 
ferroportin (the major transporter of iron) expre-
ssion and iron transferring from duodenal mucosa 
to the plasma [18]. The main part of exported iron 
from duodenal mucosa by the ferroportin is used 
to sustain de novo erythropoiesis [19]. It has been 
VKRZQ WKDWKDSWRJORELQQXOOPLFHH[SRUW VLJQL¿-
cantly more iron from the duodenal mucosa to the 
plasma compared to the control counterparts [18]. 
Few studies have shown the effects of serum HP 
concentration and its genotypes on body iron sta-
tus [19, 20] and their association with hemoglobin 
level is not fully elucidated. We hypothesized that 
+3FDQLQÀXHQFHRQKHPRJORELQOHYHOVWKHUHIRUH
this study aimed to evaluate the probable relati-
onship between hemoglobin levels with HP serum 
OHYHOLWVJHQRW\SHVDQGLQÀDPPDWLRQLQ&.'VWD-
ge 4 patients with anemia.
Materials and methods
Patients and Study Design  
The study was performed in the Department of 
Biochemistry of Tabriz University of Medical Sci-
ences (TUMS). The ethics committee of TUMS 
approved the study. Recruitment of the patients 
occurred from Mar 2011 through Oct 2012. Forty 
patients (15 males and 25 females) were included 
LQWKHVWXG\$QHPLFDGXOWSDWLHQWV\UZKR
KDG&.'VWDJHZLWK*)5 POPLQ
m2ZHUHLQFOXGHGLQWKHVWXG\$QHPLDZDVGH¿-
ned as hemoglobin levels of less than 13 g/dl for 
men and postmenopausal women and less than 
12 g/dl for premenopausal women [21]. Subjects 
with transfusion within past 6 months, myocardial 
infarction history within past 3 months, surgical 
history within past 3 months, malignancy, diasto-
lic blood pressure greater than 100 mm/hg, un-
controlled diabetes, severe hyperparathyroidism 
(PTH > 800 pg/ml) and consumers of drugs such 
as angiotensin receptor blockers and angiotensin-
converting enzyme inhibitors were excluded from 
the study. 
Biochemical assays
Blood samples were obtained after an over-
night fast and hemoglobin and hematocrit levels 
were measured by blood cell counter (Sysmex 
KX-21N, Japane). Separated Serum and whole 
blood were kept frozen at –80oC until analysis. 
The serum was analyzed using an auto-analyzer 
(BT3000, Italy) and manufacture’s reagent kits for 
Mg, hs-CRP, TIBC, Fe, Ca, P, Urea, Cr, Alb and 
Total protein. Serum HP and ferritin levels were 
assayed by standard enzyme linked immunosor-
bent assay (ELISA) kits (Cusabio and DiaPlus, 
China, USA, respectively). Serum concentrations 
of IL-6 were measured using human ELISA kits 
according to the manufacturer’s instructions (Ben-
der Med Systems, Vienna, Austria). These bioche-
mical factors were assayed using fully automated 
ELISA analyzer (TKA Teknolabo Bizet, Italy). 
The PTH Chemiluminescent Activity Assay kit is 
designed to measure PTH activity (Liaison, USA) 
and GFR was calculated by the Cockcroft-Gault 
formula [22].
Haptoglobin genotyping
Genomic DNA was extracted from peripheral 
blood leukocytes using the 5-prime ArchivePure 
DNA blood kit (Ipsogen, Germany). The primer 
VHTXHQFHVXVHGIRUDPSOL¿FDWLRQRI+3DQG+3
alleles were previously described [23] and listed 
in Table1. The primers A and B were designed to 
JHQRW\SLQJ WKH+3DOOHOHVYLD DPSOL¿FDWLRQRI D
1757-bp length of fragment responsible for HP1 
DOOHOHDQGDESOHQJWKRI+3DOOHOHVSHFL¿F
sequence [23]. Detecting the HP2 allele was carri-
HGRXWE\DPSOL¿FDWLRQRIDESIUDJPHQWZLWK
primer C and D, as well. The 20µL reactions con-
tained 2 U of Taq polymerase (Fermentas Co, Ca-
nada), 1–100 ng of DNA, and 200µM dNTPs mix; 
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PCR buffer was used as suggested by the supplier 
(Fermentas Co, Canada) with no supplements ad-
ded. After initial denaturation at 95 °C for 5 min, 
the two-step thermo cycling procedure consisted 
of denaturation at 94 °C for 45 second and annea-
ling at 62 °C for 1 min (in the presence of primers 
A, B, C, and D), and extension at 72 °C for 1 min, 
UHSHDWHG IRU  F\FOHV DQG IROORZHG E\ D ¿QDO
extension at 72 °C for 7 min. The thermocycler 
instrument used was Veriti 96 well (Applied Bi-
osystems, USA). For genotype assignments, the 
3&5SURGXFWVZHUHVHSDUDWHG LQDJDURVHJHO
(Sigma-Aldrich Co, USA). 
7KHDFFXUDF\RIJHQRW\SLQJZDVFRQ¿UPHGE\
5)/3DQDO\VLV7KHES+3DOOHOH±VSHFL¿F
fragment is digested by MlsI enzyme (Fermentas 
Co, Canada) to two 551- and 1206-bp fragments. 
Presence of HP2 allele could be detected by dige-
VWLQJWKHESDPSOL¿HGSURGXFWZLWK'UD,UH-
striction enzyme (Fermentas Co, Canada) which 
produced two 193- and 156-bp fragments. After 
HYDOXDWLQJ WKH DFFXUDF\ RI DPSOL¿FDWLRQ E\ WZR
separated primer pairs and PCR-RFLP, they were 
analyzed by sequencing and blasting them for 
DSSURDFKLQJFRQ¿GHQFHRIJHQRW\SLQJ
Statistical analysis
The collected data were analyzed by statistical 
methods such as tables and Chi-square, analysis of 
YDULDQFHDQG3HDUVRQ¶V&RUUHODWLRQ&RHI¿FLHQWLQ
6366VRIWZDUHYHUVLRQ)RUDOOWHVWVDSYDOXH
ZDVFRQVLGHUHGVWDWLVWLFDOO\VLJQL¿FDQW
Results
Clinical features of study subjects were shown 
in Table 2. Results of PCR genotyping and RFLP 
for alleles of HP1 and HP2 were displayed in Fi-
gure 1. The mean age of all patients was 55.68 ± 
14.4 years old. As indicated in table 3, of 40 ca-
VHVZHUHPDOHDQGIHPD-
le. Our results showed that HP2-2 was the most 
common genotype detected; however patients 
with HP1-2 were predominantly male. The pati-
ents were divided into low (6-9 g/dl) and high he-
moglobin levels (9-13 g/dl). The results showed 
WKDWDQGRIVXEMHFWVKDGVH-
rum low and high hemoglobin levels, respectively. 
Although, the low levels of hemoglobin were seen 
in subjects with HP1-2 genotype, but there was 
QR VLJQL¿FDQW UHODWLRQVKLS EHWZHHQ KHPRJORELQ
7DEOH7KHVHTXHQFHVRIWKHSULPHUVXVHGIRU3&5DPSOL¿FDWLRQRI+3DQG+3DOOHOHV
Primer Sequence 6SHFL¿FDOOHOH Fragment size
A '-GAGGGGAGCTTGCCTTTCCATTG-3'
HP1 & HP2
HP1:1757-bp
HP2:3481-bpB 5'-GAGATTTTTGAGCCCTGGCTGGT-3'
C 5'-CCTGCCTCGTATTAACTGCACCAT-3'
HP2 349-bp
5'-CCGAGTGCTCCACATAGCCATGT-3'
Table 2. Clinical features of the study subjects
Variable Mean±SE Variable Mean±SE Variable Mean±SE
Urea (mg/dl) 126.38 ± 7.12 P (mg/dl) 4.36 ± 0.12 IL-6 (pg/ml)  0.59 ±3.39 
Cr (mg/dl) 3.66 ± 0.15 Hb (g/dl) 10.01 ± 0.24 hs-CRP (mg/l) 10.54 ± 1.89
TIBC (µg/dl) 295.05 ± 8.18 +&7 31.15 ± 0.69 Ferritin (µg/l) 163.83 ± 24.69
Fe (µg/dl) 63.5 ± 4.64 HP (mg/dl) 62.45 ± 9.31 PTH (pg/ml) 111.93 ± 13.35
Ca (mg/dl) 9.03 ± 0.11 Alb (g/dl) 4.21 ± 0.11
GFR (ml/min/1.73 
m2)
21.51 ± 0.74
Mg (mg/dl) 2.01 ± 0.04
Total 
protein(g/dl)
8.11 ± 0.17 Weight (kg) 72.4 ± 1.73
Cr= Creatinine, TIBC= Total Iron Binding Capacity, Fe= Iron, Ca= Calcium, Mg= Magnesium, P= Phosphorus, HCT= He-
PDWRFULW+3 +DSWRJORELQ$OE $OEXPLQ,/ LQWHUOHXNLQ37+ SDUDWK\URLGKRUPRQH*)5 *ORPHUXODU¿OWUDWLRQUDWH
Table 3. Distribution of gender and the level of hemoglobin between the different HP genotypes
Genotype Total frequency * Male * Female * Hemoglobin level (g/dl)±SE
HP1-1 12.5 20 80 10.54 ± 0.44
HP1-2 15 66.7 33.3 9.35 ± 1.04
HP2-2 72.5 34.5 65.5 10.05 ± 0.26
*The results are noted as percentage
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OHYHO DQG+3JHQRW\SH S 7KHUHZDVQR
VLJQL¿FDQWUHODWLRQVKLSEHWZHHQ+3JHQRW\SHDQG
VHUXP+3OHYHOS 1RPHDQLQJIXOUHODWL-
on was observed between hemoglobin level and 
VHUXP+3OHYHOS KRZHYHUWKHUHZDVDVL-
JQL¿FDQWSRVLWLYHFRUUHODWLRQEHWZHHQKHPRJORELQ
level with ferritin and albumin levels. We found 
D VLJQL¿FDQW QHJDWLYH UHODWLRQVKLS DPRQJKHPR-
JORELQOHYHOZLWK,/DQGKV&53SDQG
SUHVSHFWLYHO\7KHUHZDVDVLJQL¿FDQWSR-
sitive correlation between serum magnesium and 
KHPRJORELQOHYHOS
Discussion
CKD is a worldwide public health problem 
[24]. Anemia is one of the main problems of CKD 
DQGRFFXUVHVSHFLDOO\LQWKH¿QDOVWDJHVRIWKHGL-
sease [25]. It has been shown that the anemia is 
associated with lower quality of life and a higher 
risk of adverse outcomes including cardiovascu-
ODUGLVHDVHDQG¿QDOO\GHDWK>@+3LVRQHRIWKH
plasma proteins that may affect hemoglobin level 
and the anemia [27]. In the present study we did 
QRW¿QGDVLJQL¿FDQWUHODWLRQVKLSDPRQJKHPRJOR-
bin level with different HP genotypes and serum 
+3OHYHO,QFRQWUDVWZLWKRXU¿QGLQJVVRPHRWKHU
studies in animal model, thalasemic patients and 
patients with bone marrow failure syndromes have 
VKRZQDVLJQL¿FDQWSRVLWLYHUHODWLRQVKLSEHWZHHQ
hemoglobin level with HP genotype and serum HP 
level [19, 28, 29]. In other studies Atkinson et al 
IRXQGDSRVLWLYHVLJQL¿FDQW UHODWLRQVKLSEHWZHHQ
HP genotype and hemoglobin level in healthy su-
bjects [30, 31]. This inconsistency may be due to 
IDFWRUVVXFKDVLQÀDPPDWLRQKHSDWLFG\VIXQFWLRQ
uremic toxins and renal failure in CKD patients 
that can change hemoglobin and HP levels [16, 25, 
32, 33]. Several studies have indicated that there 
H[LVWV LQÀDPPDWLRQ LQ&.'SDWLHQWV >@ LWKDV
EHHQ VKRZQ WKDW LQÀDPPDWLRQ LQFUHDVHV SODVPD
HP concentration up to 3- to 8-fold by increased 
OHYHOV RI SURLQÀDPPDWRU\ F\WRNLQHV HJ ,/
>@$OVRLQÀDPPDWRU\PHGLDWRUVVXFKDVLQWHU-
leukins and tissue necrosis factor, blunt the effect 
of erythropoietin on the bone marrow, suppress the 
growth of erythroid colony-forming units (CFU-
E), downregulate the expression of erythropoietin 
receptors on erythroid progenitors and disrupt iron 
recycling by blocking its release from reticuloen-
dothelial cells [24]. Thus, in CKD patient’s chronic 
DQGVHYHUHLQÀDPPDWLRQ>@PD\UHVXOWLQGLVUXS-
tion of the balance between hemoglobin and HP 
levels. Reduction in levels of HP through losing 
from kidneys, decreased synthesis in liver and re-
duced erythrocyte life span due to uremic toxins 
can exacerbate this imbalance [5, 33, 35]. In the 
best of our knowledge there are no reports on re-
lationship among hemoglobin level with different 
HP genotypes and serum HP level in CKD stage 4 
and it needs further investigation to be elucidated.
:H REVHUYHG VLJQL¿FDQW LQYHUVH DVVRFLDWLRQ
among hemoglobin level with hs-CRP and IL-6. 
7KH SUHYDOHQFH RI LQÀDPPDWLRQ LQ XUHPLF SDWL-
Figure 1. Gel electrophoresis for determining haptoglobin genotypes
$*HQRW\SLQJE\3&5SULPHUV$%DQG&'/DQH.E'1$ODGGHU/DQH+3DPSOL¿HGIUDJPHQWZLWK
bp length for genotype 2 and 1757 bp length fragment for genotype 2); Lane 3, 349 bp length fragment for showing pre-
VHQFHRIDOOHOH/DQHES'1$ODGGHU8VLQJSULPHUVSDLU&DQG'FRQ¿UPHGWKHDFFXUDF\RIJHQRW\SLQJE\WKH$
and B pair.
%'LJHVWLQJWKHDOOHOHUHODWHGDPSOL¿HGIUDJPHQWVE\'UD,IRUDSSURDFKLQJWKHDFFXUDF\RIJHQRW\SLQJ/DQH	
100 bp DNA ladder. Lane 2, uncut fragment. Lane 3, cut fragments. 
&&RQ¿UPLQJWKHDFFXUDF\RIDOOHOHUHODWHGIUDJPHQWE\0OV,GLJHVWLRQ/DQH.ES'1$ODGGHU/DQHXQFXWIUD-
gment. Lane 3, cut fragments. Lane 4, 100 bp DNA ladder.   
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ents is high [36]. Several studies have revealed a 
strong relationship between anemia and chronic 
LQÀDPPDWLRQDQGVXJJHVWWKDWFKURQLFLQÀDPPD-
tion is associated with lower hemoglobin concen-
trations even in the early stages of CKD [36-38]. 
2XU¿QGLQJVDUHLQDJUHHPHQWZLWKWKH¿QGLQJVRI
other studies showed that an inverse relationship 
EHWZHHQ KHPRJORELQ OHYHO DQG LQÀDPPDWRU\
factors such as hs-CRP and IL-6 [39, 40]. Other 
independent support for this hypothesis is provi-
ded by the observation that end stage renal disea-
se patients with elevated blood levels of IL-6 are 
more anemic, and this anemia is correlated with 
increased cytokine levels [41]. Evidence suggests 
VHYHUDOPHFKDQLVPVE\ZKLFKLQÀDPPDWLRQPD\
affect the development of anemia [9]. Elevated le-
YHOVRILQÀDPPDWRU\F\WRNLQHVHQKDQFHGR[LGDWL-
ve stress and alterations in iron metabolism, con-
GLWLRQVDVVRFLDWHGZLWKLQÀDPPDWRU\VWDWHVPD\
be implicated in the development of anemia [37, 
@+RZHYHULQÀDPPDWLRQLQGXFHGDQHPLDDQG
resistance to erythropoietin are common features 
in patients with advanced CKD [24]. In dialysis 
patients, high CRP levels are associated with low 
Hb levels and/or erythropoietin resistance [36]. 
7KH LQFUHDVHG OHYHOV RI LQÀDPPDWRU\ F\WRNLQHV
such as IL-6 lead to impaired ability of RBC pro-
genitors to respond to erythropoietin, shortened 
red blood cell survival and decreased the Hb con-
FHQWUDWLRQ>@+HQFHFKURQLFLQÀDPPDWLRQLV
an important cause for decreased in Hb level in 
CKD stage 4. 
:H DOVR IRXQG D VLJQL¿FDQW SRVLWLYH UHODWL-
onship between hemoglobin and ferritin levels 
ZKLFKLVVLPLODUWRSUHYLRXV¿QGLQJV>@6DLJRHW
al in myelodysplastic syndrome [44] and Locatelli 
et al in chronic hemodialysis patients [45] showed 
DVLJQL¿FDQWQHJDWLYHUHODWLRQVKLSEHWZHHQIHUUL-
tin and hemoglobin levels, quite the opposite to 
RXU¿QGLQJV7KHVH¿QGLQJVFRQWUDVWZLWKWKRVHRI
&D]]RODHWDOZKRGLGQRWIRXQGDVLJQL¿FDQWUH-
lationship between hemoglobin and ferritin levels 
in systemic-onset juvenile chronic arthritis [46]. 
Availability of iron is key for optimal erythropoi-
esis and serum ferritin levels in healthy individu-
DOVUHÀHFWWKHPDJQLWXGHRIWKHPRELOL]DEOHERG\
iron stores, i.e., the iron that is available for the 
synthesis of hemoglobin in red blood cells [47]. It 
has been reported that the hemoglobin and ferri-
WLQ ELRPDUNHUVZHUH LQÀXHQFHGE\ LQÀDPPDWLRQ
[48]. Serum ferritin is an acute phase protein and 
LQFUHDVHVWZRWRIRXUIROGLQUHVSRQVHWRLQÀDPPD-
tion [36]. Studies in cellular and animal models 
LQGLFDWHWKDWLQÀDPPDWRU\F\WRNLQHVVXFKDV,/
can enhance ferritin synthesis and increase hepa-
tic uptake of serum iron [46]. In turn, increased 
ferritin expression results in reticuloendothelial 
iron block and impairs iron absorption [46]. In-
ÀDPPDWLRQ OHDGV WR EORFNDJH LQ LURQ XWLOL]DWLRQ
and “anemia of chronic disease [49]. Studies have 
VKRZQWKDWWKHUHLVDVLJQL¿FDQWDVVRFLDWLRQEHWZH-
en serum ferritin level and the degree of severity 
of anemia [50, 51]. More studies are needed to 
correlate ferritin and hemoglobin level in patients 
CKD stage 4 with anemia.
 ,Q RXU VWXG\ WKHUHZDV D VLJQL¿FDQW SRVLWLYH
relationship between hemoglobin and albumin le-
YHOV>@6LJQL¿FDQWSRVLWLYHUHODWLRQVKLSEHWZH-
en hemoglobin and albumin has been shown also 
LQRWKHUVWXGLHV>@7KLV¿QGLQJVXJJHVWVWKDW
anemia is also associated with both cytokine-de-
SHQGHQWLQÀDPPDWLRQDQGQXWULWLRQDOVWDWXVRISD-
tients. 
Conclusion
In conclusion, our study suggests that HP ge-
notype and serum HP levels have no effect on 
hemoglobin level in CKD stage 4. However, Hb 
OHYHOLVDVVRFLDWHGZLWKLQÀDPPDWLRQDQGDOEXPLQ
VWDWXV7KLV¿QGLQJVXJJHVWVWKDWDQHPLDLQWKHVH
patients is associated with both cytokine-depen-
GHQW LQÀDPPDWLRQ DQG QXWULWLRQDO VWDWXV RI SDWL-
ents. 
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